Literature DB >> 12142355

Genetic and epigenetic alterations in colon cancer.

William M Grady1, Sanford D Markowitz.   

Abstract

Colorectal cancer affected approximately 135,000 people in the United States in 2001, resulting in 57,000 deaths. Colorectal cancer develops as the result of the progressive accumulation of genetic and epigenetic alterations that lead to the transformation of normal colonic epithelium to colon adenocarcinoma. The loss of genomic stability is a key molecular and pathophysiologic step in this process and serves to create a permissive environment for the occurrence of alterations in tumor suppressor genes and oncogenes. Alterations in these genes, which include APC, CTNNB1, K-RAS, MADH4/SMAD4, and TGFBR2, appear to promote colon tumorigenesis by perturbing the function of signaling pathways, such as the TGF-ss signaling pathway, or by affecting genes that regulate genomic stability, such as the mutation mismatch repair genes.

Entities:  

Mesh:

Year:  2002        PMID: 12142355     DOI: 10.1146/annurev.genom.3.022502.103043

Source DB:  PubMed          Journal:  Annu Rev Genomics Hum Genet        ISSN: 1527-8204            Impact factor:   8.929


  99 in total

1.  LncRNA SUMO1P3 drives colon cancer growth, metastasis and angiogenesis.

Authors:  La-Mei Zhang; Ping Wang; Xiao-Min Liu; Ying-Jian Zhang
Journal:  Am J Transl Res       Date:  2017-12-15       Impact factor: 4.060

Review 2.  DNA alkylation and DNA methylation: cooperating mechanisms driving the formation of colorectal adenomas and adenocarcinomas?

Authors:  William M Grady; Cornelia M Ulrich
Journal:  Gut       Date:  2007-03       Impact factor: 23.059

3.  15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers.

Authors:  Min Yan; Ronald M Rerko; Petra Platzer; Dawn Dawson; Joseph Willis; Min Tong; Earl Lawrence; James Lutterbaugh; Shilong Lu; James K V Willson; Guangbin Luo; Jack Hensold; Hsin-Hsiung Tai; Keith Wilson; Sanford D Markowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-01       Impact factor: 11.205

4.  Overexpression of OATP1B3 confers apoptotic resistance in colon cancer.

Authors:  Wooin Lee; Abbes Belkhiri; A Craig Lockhart; Nipun Merchant; Hartmut Glaeser; Elizabeth I Harris; M Kay Washington; Elizabeth M Brunt; Alex Zaika; Richard B Kim; Wael El-Rifai
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

5.  Inhibition of apoptosis in normal and transformed intestinal epithelial cells by cAMP through induction of inhibitor of apoptosis protein (IAP)-2.

Authors:  Hiroshi Nishihara; Shinae Kizaka-Kondoh; Paul A Insel; Lars Eckmann
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-01       Impact factor: 11.205

6.  Non-canonical WNT5A signaling up-regulates the expression of the tumor suppressor 15-PGDH and induces differentiation of colon cancer cells.

Authors:  Lubna M Mehdawi; Chandra Prakash Prasad; Roy Ehrnström; Tommy Andersson; Anita Sjölander
Journal:  Mol Oncol       Date:  2016-08-01       Impact factor: 6.603

Review 7.  Transforming growth factor beta (TGF-beta) and inflammation in cancer.

Authors:  Brian Bierie; Harold L Moses
Journal:  Cytokine Growth Factor Rev       Date:  2009-12-16       Impact factor: 7.638

8.  Diet and epigenetics in colon cancer.

Authors:  Minna Nystrom; Marja Mutanen
Journal:  World J Gastroenterol       Date:  2009-01-21       Impact factor: 5.742

9.  Transformation by oncogenic Ras expands the early genomic response to transforming growth factor beta in intestinal epithelial cells.

Authors:  Carl E Allen; Jianguo Du; Bo Jiang; Qin Huang; Adam J Yakovich; John A Barnard
Journal:  Neoplasia       Date:  2008-10       Impact factor: 5.715

10.  Aberrant DNA methylation occurs in colon neoplasms arising in the azoxymethane colon cancer model.

Authors:  Scott C Borinstein; Melissa Conerly; Slavomir Dzieciatkowski; Swati Biswas; M Kay Washington; Patty Trobridge; Steve Henikoff; William M Grady
Journal:  Mol Carcinog       Date:  2010-01       Impact factor: 4.784

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.